Home > Insider Trading > Filing (0001140361-14-026587)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1031927	Echo Therapeutics Inc.	ECTE	Electromedical & Electrotherapeutic Apparatus (3845)	411649949

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1120642	Uri Landesman	30 00 47Th Ave Long Island City NY 11101	No	No	Yes	No
1299265	Platinum Partners Value Arbitrage Fund, Lp	C/O Walkers Corporate Services Limited Walker House, 87 Mary Street Georgetown, Grand Cayman E9 KY1-9002	No	No	Yes	No
1339643	Mark Nordlicht	152 West 57Th Street 4Th Floor New York NY 10019	No	No	Yes	No
1368616	Platinum Management (Ny) Llc	152 West 57Th Street 4Th Floor New York NY 10019	No	No	Yes	No
1404598	Platinum-Montaur Life Sciences, Llc	152 West 57Th Street 4Th Floor New York NY 10019	No	No	Yes	No
1476165	L.p. Fund Master Opportunity Liquid Partners Platinum	152 West 57 Street, 4Th Floor New York NY 10019	No	No	Yes	No
1582140	Platinum Liquid Opportunity Management (Ny) Llc	152 West 57Th Street 4Th Floor New York NY 10019	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-06-20	16,490	$2.20	594,942	No	4	P	Indirect	By Platinum Partners Liquid Opportunity Master Fund L.P.
Common Stock	Acquisiton	2014-06-23	85	$2.20	595,027	No	4	P	Indirect	By Platinum Partners Liquid Opportunity Master Fund L.P.
Common Stock	Acquisiton	2014-06-24	386	$2.20	595,413	No	4	P	Indirect	By Platinum Partners Liquid Opportunity Master Fund L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Platinum Partners Liquid Opportunity Master Fund L.P.
No	4	P	Indirect	By Platinum Partners Liquid Opportunity Master Fund L.P.
No	4	P	Indirect	By Platinum Partners Liquid Opportunity Master Fund L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,605,424	Indirect	By Platinum Partners Value Arbitrage Fund L.P.

Footnotes

This Form 4 is filed jointly by Platinum Partners Value Arbitrage Fund L.P. ("PPVA"), Platinum Partners Liquid Opportunity Master Fund L.P. ("PPLO"), Platinum-Montaur Life Sciences, LLC ("Platinum-Montaur"), Platinum Management (NY) LLC ("Platinum Management"), Platinum Liquid Opportunity Management (NY) LLC ("Platinum Liquid Management"), Mark Nordlicht and Uri Landesman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
Securities owned directly by PPLO. Each of Platinum Liquid Management, as the Investment Manager of PPLO, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Liquid Management, may be deemed to beneficially own the securities owned directly by PPLO.
Securities owned directly by PPVA. Each of Platinum Management, as the Investment Manager of PPVA, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Management, may be deemed to beneficially own the securities owned directly by PPVA.